Mostrar el registro sencillo del ítem

dc.contributor.authorBernardo, Miquel
dc.contributor.authorRico-Villademoros, Fernando
dc.contributor.authorGarcía Rizo, Clemente
dc.contributor.authorRojo, Rosa
dc.contributor.authorGómez Huelgas, Ricardo
dc.date.accessioned2021-05-07T11:19:51Z
dc.date.available2021-05-07T11:19:51Z
dc.date.issued2021-04-07
dc.identifier.citationBernardo, M., Rico-Villademoros, F., García-Rizo, C. et al. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies. Adv Ther (2021). [https://doi.org/10.1007/s12325-021-01689-8]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/68392
dc.descriptionThis independent research and manuscript writing and editing activities were funded by unconditional grant from Angelini Pharma Espan˜a SLU. Angelini Pharma Espan˜a SLU also funded the journal’s rapid service fee.es_ES
dc.descriptionThe authors thank Isabel San Andre´s (Incimed, Madrid, Spain) for performing the literature searches_ES
dc.descriptionThis article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.es_ES
dc.description.abstractIntroduction To assess the risk of occurrence and potential determinants of metabolic disorders in adult patients treated with second-generation antipsychotics (SGAs) under real-world practice conditions. Methods MEDLINE, EMBASE, and PsycInfo were searched in July 2019 from database inception. We included population-based, longitudinal, comparative studies that report the results of the outcomes of interest for adult participants, including diabetes, ketoacidosis, hyperosmolar hyperglycemic state, weight gain/obesity, dyslipidemia, hypertension, and metabolic syndrome. Two reviewers independently extracted data on the study design, study quality, and study outcomes. Results We included 40 studies. Most studies showed that clozapine and olanzapine were associated with an increased likelihood of developing diabetes, while the results for risperidone and quetiapine were mixed. Although less well studied, ziprasidone and aripiprazole appeared to not be associated with the occurrence of diabetes. Information on antipsychotic-induced weight gain/obesity is extremely scarce. Regarding dyslipidemia, aripiprazole was not associated with an increased likelihood of developing dyslipidemia, clozapine was associated with an increased likelihood of developing dyslipidemia, and risperidone, olanzapine, quetiapine, and ziprasidone showed mixed results. Two studies suggested an association between ziprasidone and the occurrence of hypertension. Several studies found that the occurrence of a metabolic disorder acted as a risk factor for the development of other metabolic disorders. We did not find information on brexpiprazole, cariprazine, or lurasidone, and data on any long-acting SGA were lacking. Conclusion Although there are relevant differences among SGAs concerning the risk of metabolic disorders, it appears that none of the SGAs included in our review are fully devoid of these disturbances.es_ES
dc.description.sponsorshipAngelini Pharma Espana SLUes_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsAtribución-NoComercial 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.subjectAntipsychotices_ES
dc.subjectDiabetes es_ES
dc.subjectDyslipidemiaes_ES
dc.subjectHyperosmolar hyperglycemic statees_ES
dc.subjectHypertension es_ES
dc.subjectKetoacidosises_ES
dc.subjectMetabolic syndromees_ES
dc.subjectObesity es_ES
dc.subjectWeight gaines_ES
dc.titleReal-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studieses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1007/s12325-021-01689-8
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 3.0 España